Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Alison Tonks
| The first 150 words of the full text of this article appear below. |
GlaxoSmithKline, a leading drugs manufacturer, was last week forced to admit that paroxetine, a widely prescribed antidepressant and the company's best selling drug, can cause severe withdrawal symptoms when stopped.
The Food and Drug Administration in the United States published a new product warning about the drug, and in the same week the International Federation of Pharmaceutical Manufacturers Associations declared the company guilty of misleading the public about paroxetine on US television a year ago.
"This drug has been promoted for years as safe and easy to discontinue," said Charles Medawar, head of Social Audit, a consumer research group specialising in medicines policy. "The fact that it can cause intolerable withdrawal symptoms of the kind that could lead to dependence is enormously important to patients, doctors, investors, and the company.
"GlaxoSmithKline has evaded the issue since it was granted a licence
for paroxetine over 10 years ago, and the drug has
Read all Rapid Responses
UK medical students have published unreleased government plans to restrict failed asylum seekers' access to medical care